ClinicalTrials.gg
CompletedNCT05942794Updated Sep 2, 2026

Identification of Oral Lesions Through an Autofluorescence System

An interventional study of Screening examination in Oral Leukoplakia, Autofluorescence and Secondary Prevention, sponsored by Federico II University. Completed at 1 site in Italy. Open to participants aged 18 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-09-02.

Sponsored by Federico II University · Not applicable, Interventional, and Screening

Phase
Not applicable
Study type
Interventional
Enrollment
200
Allocation
Not applicable
Ages
18 Years to 70 Years
Sex
All
01

Study summary

The aim of the study will be to evaluate the efficacy of a tissue autofluorescence detection system as an aid to clinical screening in identifying lesions of the oral mucosa. The screening process will be performed by 3 clinicians with a different level of experience. Sensitivity and specificity tests will be conducted.

Read the detailed description

Tissue autofluorescence analysis will be performed using GOOCLES® glasses, a device capable of detecting variations in fluorescence when the examined area is illuminated with a common photopolymerising lamp. Three clinical professionals will be identified:

  • Dental hygienist (1);
  • General dentist (2);
  • Dentist expert in Medicine and Oral Pathology (3).

All patients will be included in the study after receiving an initial dental visit, in order to rule out patients with noticeable oral lesions.

Dental hygienist (1) will collect the patient's data by filling the "anamnestic record". Furthermore, (1) will perform the first clinical examination (with and without GOOCLES®), reporting his observations on his own "operator module".

The same screening (with and without GOOCLES®) will be conducted blindly by the general dentist (2) who, if he deems it necessary, will refer the patient to the oral pathologist (3), who will confirm or not (with and without GOOCLES®) the presence of an oral region such as to be further investigated (follow up or biopsy) and will report the observations on its own "operator module".

Inter-operator and intra-operator comparisons will be performed and the data thus obtained will be processed for statistical processing.

02

Conditions studied

  • Oral Leukoplakia
  • Autofluorescence
  • Secondary Prevention
  • Keratosis
  • Oral Lichen Planus
  • Oral Cancer
  • Oral Disease

Keywords

  • Oral Leukoplakia
  • Lichen Planus
  • Squamous cell carcinoma
  • Keratosis
03

In context

Leukoplakia, Oral

48 studies on the registry are indexed under Leukoplakia, Oral; 11 are open to participants now.

This study's enrollment of 200 is above the median of 36 across 23 interventional studies indexed under Leukoplakia, Oral.

Browse Leukoplakia, Oral studies →

Lead sponsor

Federico II University is the lead sponsor of 366 studies on the registry; 61 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male and female;
  • Age ≥ 18 years;
  • Non-smokers and smokers

Exclusion criteria

Exclusion Criteria:

  • Cancer patients;
  • Patients presenting a histological diagnosis of oral mucosal dysplasia/carcinoma.
05

Study design

Phase
Not applicable
Primary purpose
Screening
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
200 participants (actual)

Study arms

  • Experimental
    Screening examination

    All patients will undergo a screening examination (with or without GOCCLES ® glasses) by all three operators.

    Device: Screening examination

Interventions

  • DeviceScreening examination

    After an initial clinical visit, all three operators will wear the tissue autofluorescence detection device (GOCCLES®), reporting both observations on their "operator-module".

06

What researchers measure

Primary outcomes

  1. Clinical change of oral mucosa

    Presence of a white, red, or mixed mucosal area with an exophytic or vegetative appearance or with loss of substance

    Time frame: baseline and after 21 days

  2. Fluorescence change of oral mucosa

    Presence of a mucosal area with reduced or increased fluorescence

    Time frame: baseline and after 21 day

07

Study locations

1 site
  • University of Naples Federico II
    Naples, Italy 80131, Italy
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jun 2023 to primary completion in Mar 2024, 9 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 29, 2023
First posted
Jul 12, 2023
StartActual
Jun 1, 2023
Primary completionActual
Mar 1, 2024
CompletionActual
Oct 1, 2024
Last update
Sep 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 2, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05942794
Responsible party
Luca Ramaglia (Clinical Professor, Federico II University) — Principal investigator
First posted
Jul 12, 2023
Start date
Jun 1, 2023
Primary completion
Mar 1, 2024
Completion
Oct 1, 2024
Last update
Sep 2, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion